Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolic and growth effects of growth hormone in children with Kabuki syndrome
2012-000432-26Phase 4Active
- Sponsor
- Maastricht University Medical Center+
- Start
- Mar 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of somatropin in Kabuki syndrome, sponsored by Maastricht University Medical Center+. Primary endpoints: Change in total energy expenditure (TEE) at 6 weeks and Change in height SDS after 1 year. Started Mar 2012; status: active.
02
Drugs
somatropin
03
Conditions
Kabuki syndrome
Beyond the preview
Go deeper on 2012-000432-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000432-26.